Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Foghorn Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

About Foghorn Therapeutics Inc.

Foghorn Therapeutics is a biotechnology company focused on developing precision cancer therapies by targeting the chromatin regulatory system, which controls gene expression. Using its proprietary Gene Traffic Control platform, it identifies and drug genetically defined dependencies in cancer cells. The company’s pipeline includes novel small molecule inhibitors, degraders, and disruptors, with a focus on oncology and potential applications in other diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Foghorn Therapeutics Inc.

1
1
Foghorn Therapeutics Inc. Foghorn Therapeutics Reports Q1 2026 Financial Results with $3.3M Revenue and $19.9M Net Loss

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Foghorn Therapeutics Inc. Foghorn Therapeutics Reports $30.9M Collaboration Revenue and $74.3M Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Foghorn Therapeutics Inc. Foghorn Therapeutics Reports Q3 2025 Financial Results with Improved Revenue and Reduced Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Foghorn Therapeutics Inc. Foghorn Therapeutics Reports Q2 2025 Financial Results with Increased Collaboration Revenue

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Foghorn Therapeutics Inc. Foghorn Therapeutics Reports Q1 2025 Financial Results with Improved Revenue and Reduced Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Foghorn Therapeutics Inc. Foghorn Therapeutics Reports $86.6 Million Net Loss for 2024, Decreased Collaboration Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Foghorn Therapeutics Inc. Foghorn Therapeutics Reports Q3 2024 Financial Results, Highlighting Changes in Revenue, Expenses, and Cash Position

Via official filing (AI summary) | over 1 year ago | 0 comments